PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month

PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month

Chest X-ray beside the PRISM MarketView logo, a purple awareness ribbon and the text

PRISM MarketView, a financial media platform covering small-cap public companies through 27 thematic indexes, today published a X8UY70LuDpojrMwrO4O4wK8OcR1YS4_B6vVGjwC8PvHiG_iZh8OplTUDjj65k47fzQSNdD4hHbMO1Lia3_3f1Mfo2Mn0rUuwo38qIuOKQ0RJJmhvYa2FYvfPcThgwK16TjniRWzHWPLQLF9SQycElv-FEJUyHSTjWczRUGFvPnhvb833HDw01ZKlLInRQbkYYZFEs=" target="_blank" rel="nofollow">Lung Cancer Awareness Month feature on seven small-cap companies developing therapies and diagnostics for lung cancer, the leading cause of cancer death in the U.S.

The feature follows the FDA's decision not to approve a PD-1xVEGF bispecific antibody in EGFR-mutated lung cancer after the agency concluded the data could not establish effectiveness without a statistically significant survival benefit. The decision has put clinical endpoints in focus for smaller developers working in the disease.

Candel Therapeutics (NASDAQ: CADL) and MAIA Biotechnology (NYSE American: MAIA) are running Phase 3 trials that use overall survival as their primary endpoint. Cullinan Therapeutics (NASDAQ: CGEM) and partner Taiho Oncology are awaiting an FDA decision on zipalertinib, with a target action date of February 27, 2027. Crescent Biopharma (NASDAQ: CBIO) expects proof-of-concept data for its PD-1xVEGF bispecific CR-001 in the first quarter of 2027, and Tango Therapeutics (NASDAQ: TNGX) plans to disclose lung cancer data for vopimetostat in January 2027.

Personalis (NASDAQ: PSNL) secured Medicare coverage for its NeXT Personal residual disease test in stage I to III non-small cell lung cancer, and bioAffinity Technologies (NASDAQ: BIAF) is extending its CyPath Lung test to monitoring survivors after treatment.

Read the full article on PRISM MarketView: https://prismmarketview.com/fda-rejection-of-summits-lung-cancer-drug-puts-survival-data-at-the-center-for-small-caps/

About PRISM MarketView

PRISM MarketView is a financial media and index publishing platform for investors seeking small-cap opportunities. Since 2020, PRISM has covered emerging growth companies through daily news, analysis and 27 thematic small-cap indexes spanning biotech, medtech, AI, energy and more. Learn more at prismmarketview.com.

Follow PRISM MarketView on X, LinkedIn, Instagram, TikTok and YouTube.

PRISM MarketView does not provide investment advice.

Media Contact
info@prismmarketview.com
646-863-6341

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b1585272-bd54-4c1f-9906-10b0b20882a4


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CGEM
The Conversation (0)
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in its pivotal Phase 2b REZILIENT1... Keep Reading...
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5... Keep Reading...
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations Longer term follow-up for patients... Keep Reading...
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments... Keep Reading...
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. "I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief... Keep Reading...
Longeveron Granted Small or Medium-sized Enterprise  Status by the European Medicines Agency

Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines... Keep Reading...
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...

Interactive Chart

Latest Press Releases

Related News